Ferritin Nanocarrier Traverses the Blood Brain Barrier and Kills Glioma

Citations Over TimeTop 1% of 2018 papers

Abstract

Over the last decades, considerable efforts have been put into developing active nanocarrier systems that cross the blood brain barrier (BBB) to treat brain-related diseases such as glioma tumors. However, to date none have been approved for clinical usage. Here, we show that a human H-ferritin (HFn) nanocarrier both successfully crosses the BBB and kills glioma tumor cells. Its principle point of entry is the HFn receptor (transferrin receptor 1), which is overexpressed in both BBB endothelial cells (ECs) and glioma cells. Importantly, we found that HFn enters and exits the BBB via the endosome compartment. In contrast, upon specifically targeting and entering glioma cells, nearly all of the HFn accumulated in the lysosomal compartment, resulting in the killing of glioma tumor cells, with no HFn accumulation in the surrounding healthy brain tissue. Thus, HFn is an ideal nanocarrier for glioma therapy and possesses the potential to serve as a therapeutic approach against a broad range of central nervous system diseases.

Related Papers

• → Endosomal trafficking regulates receptor-mediated transcytosis of antibodies across the blood brain barrier(2017)101 cited
• → Lymphocyte Proliferation Is Controlled by both Iron Availability and Regulation of Iron Uptake Pathways(1992)68 cited
• → [22] Receptor assay with radiolabeled transferrin(1987)13 cited
• → Species specificity of iron delivery in hybridomas(1988)11 cited
• → Commentary: Mutations of Transferrin Receptor 2 (Trf-2) and Iron Storage Disease(2001)2 cited